Delivery of temozolomide to the tumor bed via biodegradable gel matrices in a novel model of intracranial glioma with resection

Journal of Neuro-Oncology

Volumn 94, Issue 2, 2009, Pages 203-212

  Akbar, Umar ^a   Jones, Terreia ^a   Winestone, Jon ^a   Michael, Madison ^a   Shukla, Atul ^a   Sun, Yichun ^a   Duntsch, Christopher ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Brain tumor; Chemotherapeutic; Glioma; Polymer; Therapy

Indexed keywords

1 METHYL 2 PYRROLIDINONE; ACETYLTRIETHYL CITRATE; CITRIC ACID TRIETHYL ESTER; COPOLYMER; DYE; GALLOCYANIN; MACROGOL 400; PLASTICIZER; POLYLACTIC ACID CO GLYCOLIC ACID; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CANCER SURGERY; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CRANIOTOMY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GEL; GEL MATRIX FORMULATION; GLIOMA; IN VIVO STUDY; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; RAT; TUMOR VOLUME; WISTAR RAT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOCOMPATIBLE MATERIALS; BRAIN; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; GLIOMA; HUMANS; MAXIMUM TOLERATED DOSE; MICE; POLYMERS; RATS; RATS, WISTAR; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 68949122336     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-9857-9     Document Type: Article

References (26)

1. Chandler WF, Greenberg HS, Ensminger WD et al (1988) Use of implantable pump systems for intraarterial, intraventricular and intratumoral treatment of malignant brain tumors. Ann N Y Acad Sci 531:206-212. doi: 10.1111/j.1749-6632.1988.tb31829.x
2. Heimberger AB, Archer GE, McLendon RE et al (2000) Temozolomide delivered by intracerebral microinfusion is safe and efficacious against malignant gliomas in rats. Clin Cancer Res 6:4148-4153
3. Lord P, Allami H, Davis M et al (1988) MiniMed technologies programmable implantable infusion system. Ann N Y Acad Sci 531:66-71. doi: 10.1111/ j.1749-6632.1988.tb31813.x
4. Ratcheson RA, Ommaya AK (1968) Experience with the subcutaneous cerebrospinal-fluid reservoir. Preliminary report of 60 cases. N Engl J Med 279:1025-1031
5. Brem S, Tyler B, Li K et al (2007) Local delivery of temozolomide by biodegradable polymers is superior to oral administration in a rodent glioma model. Cancer Chemother Pharmacol 60:643-650. doi: 10.1007/ s00280-006-0407-2
6. Tamargo RJ, Epstein JI, Reinhard CS et al (1989) Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomed Mater Res 23:253-266. doi: 10.1002/jbm.820230209
7. Valtonen S, Timonen U, Toivanen P et al (1997) Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 41:44-48; discussion 48-49. doi: 10.1097/00006123-199707000-00011
8. Walter KA, Cahan MA, Gur A et al (1994) Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 54:2207-2212
9. Weingart JD, Thompson RC, Tyler B et al (1995) Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int J Cancer 62:605-609. doi: 10.1002/ijc.2910620519
10. Menei P, Benoit JP, Boisdron-Celle M et al (1994) Drug targeting into the central nervous system by stereotactic implantation of biodegradable microspheres. Neurosurgery 34:1058-1064; discussion 1064. doi: 10.1097/ 00006123-199406000-00016
11. Oda Y, Tokuriki Y, Tsuda E et al (1979) Trial of anticancer pellet in malignant brain tumours; 5 FU and urokinase embedded in silastic. Acta Neurochir Suppl (Wien) 28:489-490
12. Wang PP, Frazier J, Brem H (2002) Local drug delivery to the brain. Adv Drug Deliv Rev 54:987-1013. doi: 10.1016/S0169-409X(02)00054-6
13. Hochberg FH, Pruitt A (1980) Assumptions in the radiotherapy of glioblastoma. Neurology 30:907-911
14. Denny BJ, Wheelhouse RT, Stevens MF et al (1994) NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry 33:9045-9051. doi: 10.1021/bi00197a003
15. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
16. Corsa P, Parisi S, Raguso A et al (2006) Temozolomide and radiotherapy as first-line treatment of high-grade gliomas. Tumori 92:299-305
17. Mutter N, Stupp R (2006) Temozolomide: A milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther 6:1187-1204. doi: 10.1586/ 14737140.6.8.1187
18. Vera K, Djafari L, Faivre S et al (2004) Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors. Ann Oncol 15:161-171. doi: 10.1093/annonc/mdh003
19. Sun Y, Peng Y, Aksornkoae N et al (2002) Controlled release of oxytetracycline in sheep. J Control Release 85:125-134. doi: 10.1016/ S0168-3659(02)00286-9
20. Mineura K, Fushimi S, Kowada M et al (1990) Linkage between O6-methylguanine-DNA methyltransferase (O6-MT) activity and cellular resistance to anti-tumour nitrosoureas in cultured rat brain tumour cell strains. Acta Neurochir (Wien) 103:62-66. doi: 10.1007/BF01420193
21. Yang DI, Chen SD, Yang YT et al (2004) Carbamoylating chemoresistance induced by cobalt pretreatment in C6 glioma cells: Putative roles of hypoxia-inducible factor-1. Br J Pharmacol 141:988-996. doi: 10.1038/ sj.bjp.0705687
22. Kawai H, Toyohara J, Kado H et al (2006) Acquisition of resistance to antitumor alkylating agent ACNU: A possible target of positron emission tomography monitoring. Nucl Med Biol 33:29-35. doi: 10.1016/ j.nucmedbio.2005.10.002
23. Dhandapani KM, Mahesh VB, Brann DW (2007) Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NF-kappa B transcription factors. J Neurochem 102:522-538. doi: 10.1111/ j.1471-4159.2007.04633.x
24. Huang XJ, Li CT, Zhang WP et al (2008) Dihydroartemisinin potentiates the cytotoxic effect of temozolomide in rat C6 glioma cells. Pharmacology 82:1-9. doi: 10.1159/000125673
25. Kim H, Likhari P, Parker D et al (2001) High-performance liquid chromatographic analysis and stability of anti-tumor agent temozolomide in human plasma. J Pharm Biomed Anal 24:461-468. doi: 10.1016/ S0731-7085(00)00466-0
26. Reyderman L, Statkevich P, Thonoor CM et al (2004) Disposition and pharmacokinetics of temozolomide in rat. Xenobiotica 34:487-500. doi: 10.1080/00498250410001685737